Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business following a similar trajectory.

High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

After losing market share in recent years, Nike faces near-term challenges such as the sales momentum among competitors. The Federal Trade Commission sued the drug middlemen that health plans use to ...